HIMS Hims Hers Health Inc

Latest Earnings Insight

Hims & Hers Health's impressive 90% revenue surge in Q2 2025, largely driven by its $420 million GLP-1 offerings, sets a robust foundation as the company approaches its Q3 earnings announcement on November 3, 2025. Despite facing regulatory uncertainties and margin pressures, the telehealth leader has maintained investor confidence, evidenced by a 7.61% stock uptick following Deutsche Bank's optimistic outlook and adjusted price target of $48. With a market cap of over $11.6 billion, Hims & Hers is expected to report an EPS of $0.09, slightly below the whisper number of $0.11, alongside a projected revenue of $580.24 million. The company's strategic investments in vertical integration and new women's health specialties underscore its commitment to long-term growth, even as it navigates the challenges of high valuation and technical indicators suggesting caution. As Hims & Hers continues to expand its platform and capitalize on its strong retention rates and user base, the upcoming earnings report will be pivotal in assessing its trajectory towards the ambitious 2030 targets of $6.5 billion in revenue and $1.3 billion in EBITDA.